PI3 and melanoma: Figure 6 shows that both Wortmannin and LY294002 sensitized non-metastatic 4C11- (A and B, respectively) and metastatic 4C11+ (C and D, respectively) melanoma cells to anoikis. These data suggest that PI3- signaling pathway activation confers anoikis resistance to melanoma cells that overexpress Timp1.